Daily Stock Analysis, IMGN, ImmunoGen Inc, priceseries

ImmunoGen Inc. Daily Stock Analysis
Stock Information
Open
2.51
Close
2.39
High
2.46
Low
2.36
Previous Close
2.40
Daily Price Gain
-0.01
YTD High
6.12
YTD High Date
Feb 25, 2019
YTD Low
1.76
YTD Low Date
May 31, 2019
YTD Price Change
-2.39
YTD Gain
-50.00%
52 Week High
10.62
52 Week High Date
Jul 13, 2018
52 Week Low
1.76
52 Week Low Date
May 31, 2019
52 Week Price Change
-7.73
52 Week Gain
-76.38%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 30. 2016
2.04
Jan 24. 2017
2.33
15 Trading Days
14.23%
Link
LONG
Feb 23. 2017
2.61
Mar 17. 2017
3.49
16 Trading Days
33.67%
Link
LONG
May 12. 2017
4.10
May 26. 2017
4.75
10 Trading Days
15.91%
Link
LONG
Jun 19. 2017
4.91
Jul 11. 2017
6.85
15 Trading Days
39.42%
Link
LONG
Jan 9. 2018
7.40
Feb 5. 2018
8.35
18 Trading Days
12.87%
Link
LONG
Feb 14. 2018
10.15
Mar 8. 2018
10.78
15 Trading Days
6.19%
Link
LONG
Jan 4. 2019
4.94
Jan 14. 2019
5.24
6 Trading Days
6.12%
Link
Company Information
Stock Symbol
IMGN
Exchange
NasdaqGS
Company URL
http://www.immunogen.com
Company Phone
(781)895-0600
CEO
Mark J. Enyedy
Headquarters
Massachusetts
Business Address
830 WINTER ST, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000855654
About

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. Its product candidates include Mirvetuximab Soravtansine, Coltuximab ravtansine and Kadcyla . The company was founded in March 1981 and is headquartered in Waltham, MA.

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.